In HER2 + breast cancers, membrane levels of Jagged 1 can be increased by HER2 inhibitors, thereby activating ligand-dependent Notch signaling in CSCs that are resistant to trastuzumab [227]. This evidence concerns the gene ERBB2 and breast cancer.